Research programme: protein kinase inhibitors - AbbVie

Drug Profile

Research programme: protein kinase inhibitors - AbbVie

Alternative Names: A-443654; A-947864

Latest Information Update: 01 Feb 2013

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Heterocyclic bicyclo compounds; Indazoles; Pyridines; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Checkpoint kinase 1 inhibitors; Epidermal growth factor receptor antagonists; Insulin-like growth factor-I receptor antagonists; Janus kinase-2 inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 31 Mar 2010 Preclinical development is ongoing in USA
  • 20 Aug 2009 Pharmacodynamics data from an In vitro trial in Cancer presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top